Qingweishi (Everolimus) – Oncology | HongKong DengYue Medicine
- Generic Name/Brand Name: Everolimus/Qingweishi
- Indications: Oncology
- Dosage form: Oral tablets
- Specifications: 2.5 mg/5 mg/10 mg × 28 tablets
Everolimus Application Scope
Everolimus is primarily used in oncology and immunomodulatory therapy, including the treatment of certain advanced cancers, neuroendocrine tumors, tuberous sclerosis-related diseases, and immunosuppression after solid organ transplantation (specific formulations and indications vary by region).

Everolimus Characteristics
Ingredients: Everolimus
Characteristics: An oral mTOR (target of rapamycin) inhibitor
Packaging specifications: Usually available in oral tablet form, with various strengths (e.g., 2.5 mg, 5 mg, 10 mg)
Storage: Store at room temperature, away from light and moisture. Please keep the original packaging before use
Expiry date: Please refer to the specific expiry date on the product packaging
Implementation Standard: Complies with national drug regulatory standards (see local pharmacopoeia and approved product documentation)
Approval Number: Please refer to the drug marketing authorization number approved by the relevant regulatory agency
Revision date: Please refer to the latest approved product information
Manufacturer: Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
Guidelines for the Use Everolimus
Dosage and Administration:
Recommended Dosage: The recommended dosage varies depending on the indication, treatment regimen, and patient condition. Dosage adjustments may be necessary based on tolerability and clinical response.
Administrative:
Take once daily.
It can be taken with meals or on an empty stomach, but it is recommended to take it regularly.
The tablets should be swallowed whole and should not be crushed or chewed.
Missed Dose: If you miss a dose, take it as soon as you remember on the same day. If more than 6 hours have passed since the last dose, skip the missed dose. Never take a double dose.
Adverse reactions:
Common Adverse Reactions:
Stomatitis / oral ulcers
Rash
Fatigue
Infections
Metabolic abnormalities (hyperglycemia, hyperlipidemia)
- Serious Adverse Reactions:
Non-infectious pneumonitis
Severe infections
Bone marrow suppression
Renal dysfunction
Contraindications:
Known hypersensitivity to everolimus or other rapamycin derivatives
Use in patients where the risk outweighs the benefit, as determined by a physician
Precautions:
Regular monitoring of blood counts, liver and kidney function, glucose, and lipid levels is recommended
Use with caution in patients with infection risk or impaired organ function
Treatment should be managed by experienced healthcare professionals
Everolimus Interactions
Everolimus is metabolized primarily via CYP3A4.
Strong CYP3A4 inhibitors or inducers may significantly affect drug levels
Caution is required when used with other immunosuppressive or cytotoxic agents
notes:
- If the medicine has new packaging, the new packaging shall prevail. The above information is from Dengyue Pharmaceutical .
- This information is for informational purposes only. Prescription medications must be used under the guidance of a doctor and purchased from authorized sources.










Reviews
There are no reviews yet.